Share
Pradaxa (dabigatran) is a prescription blood-thinning medication approved by the Food and Drug Administration (“FDA”) to reduce the risk of stroke in people with non-valvular atrial fibrillation.
Pradaxa belongs to a class of anticoagulant drugs called direct thrombin inhibitors. These work by attaching to clotting agents in the blood and reduce its ability to clot. Pradaxa does not have a known counteracting drug, making it very difficult to stop bleeding in patients taking Pradaxa. This means that there is a significant risk of serious bleeding for the millions of people taking Pradaxa. The manufacturer of Pradaxa, Boehringer Ingelheim, has reported hundreds of fatal bleeding events since its approval.
People at the highest risk for abnormal bleeding from Pradaxa use include people who:
• are 75 years old or older,
• have existing kidney problems,
• have stomach bleeding or an ulcer,
• or are taking other drugs that increase the risk of bleeding, including aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and other blood thinners.
If you or a loved one suffered problems related to uncontrolled bleeding while taking Pradaxa, you may have a claim against the drug’s manufacturer. Please contact us to discuss your potential claim.
